Abstract:4894 The coagulation system is regularly activated in patients with cancer, especially with lung cancer and gastrointestinal tumors. Up to 30 % of these patients suffer from thromboembolic complications. Obviously, activation of thrombin occurs in the natural course of cancer. During tumor progression, many patients develop malignant effusions; treatment is complicated by increased resistance of tumor cells to chemotherapy. Thrombin-mediated activation of cellular receptor(s), such as proteinase-activated receptor-1(PAR-1), plays an important role in tumor growth, local progression, and distant metastasis. Our hypothesis is, that tumor cells that express PAR-1 have a survival benefit if they are activated by thrombin within the malignant effusion. We harvested primary cancer cells from pleural and peritoneal effusions of 110 patients with different carcinomas. In 22 cases we were able to establish long time cultures (2 pancreatic, 4 colon, 3 SCLC, 5 NSCLC, 3 mesothelioma, 1 gastric, 1 rectum, 1 breast, 1 melanoma and 1 NHL). We detected PAR-1, 3 expression using reverse transcription-polymerase chain reaction (RT-PCR) and fluorescence activated cell sorting (FACS) scan. We found that in 76% the primary cancer cells were PAR-1 positive using RT-PCR assays, and in 70% the expression of PAR-1 receptor was positive using FACS scan. In contrast, we found that PCR for PAR-3 was positive in only 37.5% and the expression of the receptor in 6%. As a sign of thrombin activation, we regularly found increased levels of prothrombin fragment F1+2 in the malignant effusions compared to serum of patients (12.0 +/− 4.1 nmol/L vs 1.9 +/− 0.4 nmol/L). In summary, we found that most of the primary cancer cells in malignant effusions exhibit a positive PAR-1 expression, but PAR-3 expression is low. Also, thrombin is activated in most malignant effusions as shown by prothrombin fragment 1+2 elevation. Further experiments will show if these cell-biological mechanisms aggravate cellular resistance in primary tumor cells found in malignant effusion in end-stage cancer. Therapeutic consequences, such as therapeutic thrombin inhibition in addition to chemotherapy are discussed.

Protease-Activated Receptors in Cancer: A Systematic Review

Proteinase-activated Receptor 1, 3 Expression in Primary Human Carcinoma Cells

Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho–Rho kinase axis and tumor microenvironment

Proteinase-Activated Receptor 1 Expression in Human Leukemia Hl-60 Cells and Its Significance.

Thrombin—unique coagulation system protein with multifaceted impacts on cancer and metastasis

Coagulation Protease-Driven Cancer Immune Evasion: Potential Targets for Cancer Immunotherapy

[Thrombin and Angiogenesis of Cancer--review].

PARs in the inflammation-cancer transformation of CRC

Parthanatos And Its Associated Components: Promising Therapeutic Targets For Cancer

Role of Protease-Activated Receptor-1 in Glioma Growth.

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications

Protease-activated receptor 2: a promising therapeutic target for women's cancers

The Urokinase Receptor (uPAR) as a “Trojan Horse” in Targeted Cancer Therapy: Challenges and Opportunities

Neutrophil extracellular traps and cancer-associated thrombosis

Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy

Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology

PAD4 and Its Inhibitors in Cancer Progression and Prognosis

TF/PAR2 Signaling Axis Supports the Protumor Effect of Neutrophil Extracellular Traps (NETs) on Human Breast Cancer Cells

Protease activated receptor-1 regulates mixed lineage kinase-3 to drive triple-negative breast cancer tumorigenesis

Microparticle Phosphatidylserine Mediates Coagulation: Involvement in Tumor Progression and Metastasis

Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy